Who
Paul Schimmel
Director
Company insider
Files Form 4 as: Director, aTyr Pharma; Director, Forte Biosciences; Director, Alnylam Pharmaceuticals; Director, Sirtris Pharmaceuticals; Director, Alkermes; Director, Repligen; Director, Avicena Group.
In numbers
- Trades disclosed
- 200
- Buys
- 33
- Sells
- 18
- Bought
- $9.3M
- Sold
- $16.7M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 31 Jan 2006
- Last trade
- 27 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 28 May 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $50K100,000 at $0.4963 | filing |
| 27 May 2026filed 28 May 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $50K100,000 at $0.50 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Oct 2025filed 9 Oct 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $299K317,999 at $0.94 | filing |
| 8 Oct 2025filed 9 Oct 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $614K682,001 at $0.90 | filing |
| 1 May 2025filed 2 May 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Jul 2024filed 24 Jul 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $101K52,300 at $1.93 | filing |
| 23 Jul 2024filed 24 Jul 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $12K6,648 at $1.82 | filing |
| 22 Jul 2024filed 24 Jul 2024 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $71K41,052 at $1.74 | filing |
| 22 May 2024filed 23 May 2024 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 10 May 2023filed 11 May 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $450K200,000 at $2.25 | filing |
| 26 Apr 2023filed 28 Apr 2023 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 26 Apr 2023filed 28 Apr 2023 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —6,000 | filing |
| 26 Apr 2022filed 28 Apr 2022 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 20 Sep 2021filed 22 Sep 2021 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $2.0M250,000 at $8.00 | filing |
| 20 Sep 2021filed 22 Sep 2021 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code G | —250,000 at $0.00 | filing |
| 20 Sep 2021filed 22 Sep 2021 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code G | —250,000 at $0.00 | filing |
| 18 May 2021filed 20 May 2021 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Bought | $199K50,000 at $3.98 | filing |
News
No headline names them, or the companies they trade most, lately.